Nevertheless, we find the effects achieved by the new AdipoRon derivatives to be quite outstanding, and the molecules here certainly serve as a starting point for the development of even better ligands with improved target specificity and PK values in order to tap into the therapeutic potential of adiponectin for combating diabetes and metabolic diseases. Here, ADIPOQ is linked to metabolic disease.